April Burbage

April L. Burbage serves as a key procurement professional within the Defense Health Agency’s HCD West office, supporting the operational readiness of military medical forces across the Indo-Pacific region. She manages the acquisition of mission-critical electromedical, diagnostic, and surgical equipment, ensuring timely delivery and sustainment of clinical capabilities in austere and high-tempo environments. Her portfolio centers on maintaining the integrity of laboratory and surgical systems through direct procurement, maintenance contracts, and modernization initiatives aligned with DHA’s strategic health readiness goals. Burbage routinely handles complex acquisitions under FAR Part 13 and Part 15, balancing urgency with compliance in high-stakes medical supply chain operations. She maintains established relationships with a core group of contractors including HealthStream Inc., Seneca Federal Solutions, LLC, AMD International Technologies LLC, Novartis Pharmaceuticals Corporation, and A.S.Y. Co., Ltd., reflecting a mix of service providers, medical device manufacturers, and diagnostic supply specialists. Her contracting patterns emphasize long-term vendor partnerships with firms capable of delivering technical support, calibration, and rapid field service for precision medical equipment, often requiring specialized certifications and defense-grade compliance. Burbage’s procurement activity is predominantly conducted under open competition, with 78.3% of awards issued without set-aside restrictions. However, she consistently allocates 21.7% of opportunities to total small business set-asides under FAR 19.5, demonstrating a measured but active commitment to small business participation without prioritizing socioeconomically designated programs such as 8(a) or HUBZone. Her technical focus is concentrated in NAICS 811210 for electronic and precision equipment repair and maintenance, alongside specialized procurement in medical instrument manufacturing (339112), analytical laboratory instrumentation (334516), and in-vitro diagnostic substance manufacturing (325413). This reflects deep expertise in sustaining the lifecycle of high-complexity medical systems critical to battlefield and garrison clinical operations.